Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability - Schedule of Fair Value of Derivative Liability (Details) - Development Derivative Liability - Level 3 - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively	$ 27,726	$ 0
Non-cash research and development expense	4,951	16,703
Cash receipts from SFJ	750	3,000
Change in the fair value of development derivative liability	(33,427)	8,023
Fair value at end of period	$ 0	$ 27,726